贝舒地尔的用药指南

Besudil mesylate tablets are a drug targeting chronic graft-versus-host disease and are suitable for patients aged 12 and above who have an inadequate response to glucocorticoids or other systemic treatments. The drug was developed by Kadmon Pharmaceuticals and later acquired by Sanofi. It will be approved for marketing in China in 2023. This article will introduce the relevant information of Besudil mesylate tablets in detail from three aspects: medication guide, side effects and medication for special groups, to help patients and medical staff better understand and use this drug.

Besudil Medication Guide

Besudil mesylate tablets are a targeted treatment drug for chronic graft-versus-host disease. Patients need to take the drug under the guidance of a doctor. The following content will introduce in detail the usage, dosage, administration and precautions of the drug.

Recommended dosage

The conventional dosage of Besudil Mesylate Tablets is 200 mg once a day, administered orally. If used in combination with a strong CYP3A inducer, the dose needs to be adjusted to 200 mg twice daily. Patients must strictly follow the doctor's instructions and are not allowed to increase or decrease the dosage on their own.

Dosing Mode

This product is an oral tablet that can be taken with food or on an empty stomach. When taking the medicine, swallow the tablet whole and do not crush, chew or dissolve the tablet. The bottle cap must be tightly closed after each dose to prevent the medicine from getting damp.

Treatment cycle

Patients need to continue taking Besudil mesylate tablets until the progression of chronic graft-versus-host disease requires new systemic treatment. Regular follow-up visits should be conducted during treatment to evaluate efficacy and safety.

Correct use of Besudil Mesylate Tablets can effectively control the symptoms of chronic graft-versus-host disease, but medical instructions must be strictly followed to avoid reduced efficacy or increased adverse reactions due to inappropriate medication.

Side effects of Besudil

Besudil mesylate tablets may cause some side effects during treatment. Patients need to understand these potential reactions and communicate with their doctors in a timely manner.

Common side effects

The most common adverse reactions include infection, fatigue, nausea, diarrhea, dyspnea, cough, edema, bleeding, abdominal pain, musculoskeletal pain, headache, etc. Abnormal laboratory test results may manifest as low serum phosphate, elevated gamma-glutamyl transferase, low lymphocyte count, and hypertension.

Serious side effects

A small number of patients may experience serious side effects such as serious infection, bleeding, or high blood pressure. If you have persistent high fever, severe bleeding, or a sharp increase in blood pressure, you should seek medical attention immediately.

Drug interactions

Besudil mesylate tablets may interact with drugs such as strong CYP3A inducers and proton pump inhibitors, which may affect drug efficacy or increase the risk of adverse reactions. Patients should inform their doctor about other medications they are taking while taking this medication.

Understanding the side effects of Besudil Mesylate Tablets can help patients detect abnormalities in time and take corresponding measures to improve the safety of treatment.

Besudil medication for special groups

Different groups of people may have different reactions to Besudil mesylate tablets. Special groups of people need to use the medication with caution under the guidance of a doctor.

Pregnant and lactating women

Besudil mesylate tablets used by pregnant women may cause harm to the fetus. They need to be used with caution after weighing the pros and cons. Lactating women should stop breastfeeding during treatment and at least 1 week after the last dose.

Children and the elderly

Safety and effectiveness in pediatric patients 12 years and older have been established, but use in pediatric patients under 12 years of age has not been determined. No significant differences were observed in patients aged 65 years and older compared with younger patients, but close monitoring is still required.

Patients of childbearing potential

Women and men of childbearing potential need to take effective contraceptive measures during treatment and for at least 1 week after the last dose to avoid potential harm to the fetus caused by the drug.

Special groups need to pay special attention when using Besudil Mesylate Tablets and follow doctor's recommendations to reduce potential risks and improve treatment effects.